Associated Press
Biotechnology company Clinical Data Inc. said this morning that the Food and Drug Administration approved the major depressive disorder treatment Viibryd. Clinical Data shares surged more than 40 percent in pre-market trading.
The Newton company said the drug should be available in U.S. pharmacies in the second quarter. Clinical Data holds exclusive worldwide rights to the drug from Germany-based Merck KGaA.
Major depressive disorder, also called major depression, is one of the most common mental disorders in the US.
Shares of Clinical Data surged $6.17, or 41 percent, to $21.20 in pre-market trading.